Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $143 | 6-8 weeks | |
5 mg | $318 | 6-8 weeks | |
10 mg | $497 | 6-8 weeks | |
25 mg | $1,070 | 6-8 weeks | |
50 mg | $1,690 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | Ansornitinib (ANG-3070) is an orally active KDR and PDGF receptor inhibitor with antifibrotic activity that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2), and may be useful for the study of diseases caused by abnormal or excessive fibrosis. |
In vitro | Ansornitinib, at concentrations ranging from 0.1 nM to 10 μM, significantly inhibits the phosphorylation of PDGFRβ in human hepatic stellate cells and KDR phosphorylation in human umbilical vein endothelial cells (HUVECs) within 2 hours[1]. |
In vivo | In 8-10 weeks TGFβ positive female mice, Ansornitinib ( 25 mg / kg ; oral administration ; twice a day ; 4 weeks ) could reduce lung fibrosis score, lung levels and αSMA, a marker of early pulmonary fibrosis[1]. |
Alias | ANG3070, ANG-3070, ANG 3070 |
Molecular Weight | 540.61 |
Formula | C30H32N6O4 |
Cas No. | 1448874-96-1 |
Storage | store at -20°C | |||||||||||||||||||||||||
Solubility Information | DMSO: 20 mg/mL (36.00 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.